{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:32:28Z","timestamp":1789497148639,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170193"],"award-info":[{"award-number":["82170193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200215"],"award-info":[{"award-number":["82200215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370197"],"award-info":[{"award-number":["82370197"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-C&T-B-08"],"award-info":[{"award-number":["2021-I2M-C&T-B-08"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2022-I2M-1-022"],"award-info":[{"award-number":["2022-I2M-1-022"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Large granular lymphocytic leukemia (LGLL) is characterized by the clonal proliferation of cytotoxic T lymphocytes or NK cells. Standard first-line immunosuppressive treatments have limitations, achieving complete remission (CR) rates of up to 50%. Immune system dysregulation is implicated in LGLL. Promising results for thalidomide, an immunomodulatory drug, combined with prednisone and methotrexate (TPM), were observed in our pilot study. This multicenter study evaluated the efficacy and safety of a thalidomide, prednisone, and methotrexate (TPM) regimen in 52 symptomatic, methotrexate- and thalidomide-naive LGLL patients from June 2020 to August 2022. Thalidomide (100\u2009mg daily for up to 24 months), prednisone (0.5\u20131.0\u2009mg\/kg every other day, tapered after 3 months), and methotrexate (10\u2009mg\/m<jats:sup>2<\/jats:sup> weekly for up to 12 months) were administered. The primary objective was to determine the CR rate. The median follow-up duration was 29.0 months (range: 4.0\u201342.0). Forty-seven patients (90.4%) achieved hematological and symptomatic responses. Thirty-nine patients (75.0%) achieved CR. The median time to response was 3.0 months (range: 3.0\u20139.0). The median progression-free survival was 40.0 months (95% confidence interval (CI): 38.0\u201342.0), and the median duration of response was 39.0 months (95% CI: 36.1\u201341.9). The most common adverse event was peripheral neuropathy (24.1%), most of which (84.6%) were grades 1\u20132. Four patients experienced grade \u22653 adverse events. In conclusion, the TPM regimen was an effective and safe treatment for symptomatic LGLL patients, with a particularly high CR rate. This trial was registered at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\" ext-link-type=\"uri\">www.clinicaltrials.gov<\/jats:ext-link> (#NCT04453345).<\/jats:p>","DOI":"10.1038\/s41392-025-02164-4","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:02:03Z","timestamp":1741737723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study"],"prefix":"10.1038","volume":"10","author":[{"given":"Ying","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengteng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-7210","authenticated-orcid":false,"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-4614","authenticated-orcid":false,"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-9151","authenticated-orcid":false,"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8621-4840","authenticated-orcid":false,"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2164_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"2164_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","volume":"129","author":"T Lamy","year":"2017","unstructured":"Lamy, T., Moignet, A. & Loughran, T. P. Jr. LGL leukemia: from pathogenesis to treatment. Blood 129, 1082\u20131094 (2017).","journal-title":"Blood"},{"key":"2164_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2019-123439","volume":"134","author":"T Lamy","year":"2019","unstructured":"Lamy, T. et al. Prospective, multicentric phase II randomized trial comparing the efficacy of methotrexate or cyclophosphamide in large granular lymphocytic leukemia: a french national study. Report on the interim analysis. Blood 134, 1545\u20131545 (2019).","journal-title":"Blood"},{"key":"2164_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/leu.2014.298","volume":"29","author":"TP Loughran Jr.","year":"2015","unstructured":"Loughran, T. P. Jr. et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29, 886\u2013894 (2015).","journal-title":"Leukemia"},{"key":"2164_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/10428194.2017.1339880","volume":"59","author":"SR Sanikommu","year":"2018","unstructured":"Sanikommu, S. R. et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk. Lymphoma 59, 416\u2013422 (2018).","journal-title":"Leuk. Lymphoma"},{"key":"2164_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/leu.2013.359","volume":"28","author":"A Moignet","year":"2014","unstructured":"Moignet, A. et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia 28, 1134\u20131136 (2014).","journal-title":"Leukemia"},{"key":"2164_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106299","volume":"90","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y. et al. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: a single-institution experience. Leuk. Res. 90, 106299 (2020).","journal-title":"Leuk. Res."},{"key":"2164_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ajh.26183","volume":"96","author":"N Dong","year":"2021","unstructured":"Dong, N. et al. Large granular lymphocytic leukemia\u2014a retrospective study of 319 cases. Am. J. Hematol. 96, 772\u2013780 (2021).","journal-title":"Am. J. Hematol."},{"key":"2164_CR9","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjh.16808","volume":"192","author":"Z Braunstein","year":"2021","unstructured":"Braunstein, Z. et al. Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. Br. J. Haematol. 192, 484\u2013493 (2021).","journal-title":"Br. J. Haematol."},{"key":"2164_CR10","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2010-07-296962","volume":"117","author":"T Lamy","year":"2011","unstructured":"Lamy, T. & Loughran, T. P. Jr. How I treat LGL leukemia. Blood 117, 2764\u20132774 (2011).","journal-title":"Blood"},{"key":"2164_CR11","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","volume":"120","author":"A Jerez","year":"2012","unstructured":"Jerez, A. et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120, 3048\u20133057 (2012).","journal-title":"Blood"},{"key":"2164_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.clml.2012.06.006","volume":"12","author":"B Bockorny","year":"2012","unstructured":"Bockorny, B. & Dasanu, C. A. Autoimmune manifestations in large granular lymphocyte leukemia. Clin. Lymphoma Myeloma Leuk. 12, 400\u2013405 (2012).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2164_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/10245332.2018.1535294","volume":"24","author":"H Sun","year":"2019","unstructured":"Sun, H., Wei, S. & Yang, L. Dysfunction of immune system in the development of large granular lymphocyte leukemia. Hematology 24, 139\u2013147 (2019).","journal-title":"Hematology"},{"key":"2164_CR14","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood-2013-03-491464","volume":"122","author":"D Cornec","year":"2013","unstructured":"Cornec, D. et al. Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy. Blood 122, 1583\u20131586 (2013).","journal-title":"Blood"},{"key":"2164_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29173-z","volume":"13","author":"J Huuhtanen","year":"2022","unstructured":"Huuhtanen, J. et al. Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8(+) T-cell large granular lymphocytic leukemia. Nat. Commun. 13, 1981 (2022).","journal-title":"Nat. Commun."},{"key":"2164_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.molmed.2017.02.006","volume":"23","author":"D Millrine","year":"2017","unstructured":"Millrine, D. & Kishimoto, T. A brighter side to thalidomide: its potential use in immunological disorders. Trends Mol. Med. 23, 348\u2013361 (2017).","journal-title":"Trends Mol. Med"},{"key":"2164_CR17","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14763","volume":"178","author":"L Li","year":"2017","unstructured":"Li, L. et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br. J. Haematol. 178, 772\u2013780 (2017).","journal-title":"Br. J. Haematol."},{"key":"2164_CR18","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal, S. et al. Antitumor activity of thalidomide in refractory multiple myeloma. New Engl. J. Med. 341, 1565\u20131571 (1999).","journal-title":"New Engl. J. Med."},{"key":"2164_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11899-020-00565-6","volume":"15","author":"H Cheon","year":"2020","unstructured":"Cheon, H. et al. Advances in the diagnosis and treatment of large granular lymphocytic leukemia. Curr. Hematol. Malig. Rep. 15, 103\u2013112 (2020).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2164_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-139481","volume":"136","author":"S Yi","year":"2020","unstructured":"Yi, S. et al. Thalidomide plus prednisone and methotrexate for symptomatic large granular lymphocyte leukemia: a prospective, single-center, pilot study. Blood 136, 23\u201324 (2020).","journal-title":"Blood"},{"key":"2164_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/sj.thj.6200149","volume":"3","author":"L Shvidel","year":"2002","unstructured":"Shvidel, L. et al. Cytokine release by activated T-cells in large granular lymphocytic leukemia associated with autoimmune disorders. Hematol. J. 3, 32\u201337 (2002).","journal-title":"Hematol. J."},{"key":"2164_CR22","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.biocel.2007.01.022","volume":"39","author":"M Melchert","year":"2007","unstructured":"Melchert, M. & List, A. The thalidomide saga. Int. J. Biochem. Cell Biol. 39, 1489\u20131499 (2007).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2164_CR23","doi-asserted-by":"publisher","first-page":"e0130078","DOI":"10.1371\/journal.pone.0130078","volume":"10","author":"S Thomas","year":"2015","unstructured":"Thomas, S. et al. Methotrexate Is a JAK\/STAT Pathway Inhibitor. PLoS ONE 10, e0130078 (2015).","journal-title":"PLoS ONE"},{"key":"2164_CR24","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1007\/s11033-020-05481-9","volume":"47","author":"V Maksimovic","year":"2020","unstructured":"Maksimovic, V. et al. Molecular mechanism of action and pharmacokinetic properties of methotrexate. Mol. Biol. Rep. 47, 4699\u20134708 (2020).","journal-title":"Mol. Biol. Rep."},{"key":"2164_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3324\/haematol.2017.175810","volume":"103","author":"SK Balasubramanian","year":"2018","unstructured":"Balasubramanian, S. K. et al. Rational management approach to pure red cell aplasia. Haematologica 103, 221\u2013230 (2018).","journal-title":"Haematologica"},{"key":"2164_CR26","doi-asserted-by":"publisher","first-page":"8229","DOI":"10.2147\/OTT.S222378","volume":"12","author":"ZY Qiu","year":"2019","unstructured":"Qiu, Z. Y., Qin, R., Tian, G. Y., Wang, Y. & Zhang, Y. Q. Pathophysiologic mechanisms and management of large granular lymphocytic leukemia associated pure red cell aplasia. OncoTargets Ther. 12, 8229\u20138240 (2019).","journal-title":"OncoTargets Ther."},{"key":"2164_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199901283400405","volume":"340","author":"R Handgretinger","year":"1999","unstructured":"Handgretinger, R. et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. New Engl. J. Med. 340, 278\u2013284 (1999).","journal-title":"New Engl. J. Med."},{"key":"2164_CR28","doi-asserted-by":"crossref","unstructured":"Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42\u201351 (2011).","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"2164_CR29","doi-asserted-by":"crossref","unstructured":"Attal, M. et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108, 3289\u20133294 (2006).","DOI":"10.1182\/blood-2006-05-022962"},{"key":"2164_CR30","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","volume":"105","author":"G Palladini","year":"2005","unstructured":"Palladini, G. et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105, 2949\u20132951 (2005).","journal-title":"Blood"},{"key":"2164_CR31","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41375-022-01555-8","volume":"36","author":"JN Wang","year":"2022","unstructured":"Wang, J. N. et al. Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent\/refractory adult Langerhans cell histiocytosis. Leukemia 36, 1619\u20131624 (2022).","journal-title":"Leukemia"},{"key":"2164_CR32","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","volume":"133","author":"L Zhang","year":"2019","unstructured":"Zhang, L. et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood 133, 1720\u20131728 (2019).","journal-title":"Blood"},{"key":"2164_CR33","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02164-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02164-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02164-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:02:07Z","timestamp":1741737727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02164-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2164"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02164-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution and with the principles of the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"85"}}